ONO 4007

Drug Profile

ONO 4007

Latest Information Update: 21 Nov 2006

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Ono Pharmaceutical
  • Class Antineoplastics; Lipopolysacchrides
  • Mechanism of Action Tumour necrosis factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 21 Nov 2006 Discontinued - Phase-I for Cancer in United Kingdom (unspecified route)
  • 21 Nov 2006 Discontinued - Phase-II for Cancer in Japan (IV)
  • 18 Jul 2000 A phase I study in solid tumours has been added to the therapeutic trials , adverse events, pharmacokinetics and pharmacodynamics sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top